Key result
Oral Angiotensin-(1-7) treatment in obese mice significantly decreased fasting plasma glucose and lipids, and modulated intestinal microbiota by increasing the Bacteroidetes/Firmicutes ratio.
Why the study?
Obesity dysregulates the renin-angiotensin system and intestinal microbiota, prompting evaluation of oral Angiotensin-(1-7) effects on the intestinal microbiota of obese mice.
Does oral Angiotensin-(1-7) improve metabolic profile and modulate intestinal microbiota in obese mice?
Does oral Angiotensin-(1-7) improve metabolic profile and modulate intestinal microbiota in obese mice?
Oral Angiotensin-(1-7) improves metabolic parameters and modulates intestinal microbiota in a mouse model of obesity, suggesting a novel therapeutic mechanism.
May support metabolic benefits of oral ANG-(1-7) in obese models; hypothesis-generating for human translation.
BACKGROUND: Obesity is a serious health problem that dysregulate Renin-Angiotensin System (RAS) and intestinal microbiota. OBJECTIVE: The present study aimed to evaluate the Angiotensin-(1-7) [ANG-(1-7)] oral formulation effects on obese mice intestinal microbiota. METHODS: Mice were divided into four groups: obese and non-obese treated with ANG-(1-7) and obese and non-obese without ANG-(1-7) during four weeks. RESULTS: We observed a significant decrease in the fasting plasma glucose, total cholesterol, triglycerides, and Low-density lipoprotein levels and increased High-density lipoprotein in animals treated with ANG-(1-7). The histological analysis showed intestinal villi height reduction in mice treated with ANG-(1-7). Additionally, increased Bacteroidetes and decreased Firmicutes (increased Bacteroidetes/ Firmicutes ratio) and Enterobacter cloacae populations were observed in the High-Fat Diet + ANG-(1-7) group. Receptor toll-like 4 (TLR4) intestinal mRNA expression was reduced in the HFD+ANG-(1-7) group. Finally, the intestinal expression of the neutral amino acid transporter (B0AT1) was increased in animals treated with ANG-(1-7), indicating a possible mechanism associated with tryptophan uptake. CONCLUSION: The results of the present study suggest for the first time an interaction between oral ANG-(1-7) and intestinal microbiota modulation.
No takes yet. Share an insight, caveat, or question.
Machado et al. (2021) studied Obesity. Oral Angiotensin-(1-7) vs. No ANG-(1-7) was evaluated on Metabolic profile and intestinal microbiota. Oral Angiotensin-(1-7) treatment in obese mice significantly decreased fasting plasma glucose and lipids, and modulated intestinal microbiota by increasing the Bacteroidetes/Firmicutes ratio.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: